CMS to cover obesity behavior therapy

Providers may be getting their load lightened a bit with help  from the Centers for Medicare & Medicaid Services. The agency has proposed covering intensive behavioral therapy for obese Medicare Part A and Part B beneficiaries.

Medicare would cover weekly personal visits for the first month; visits every two weeks for the following five months; and then monthly in-person visits the second half of the 12-month period. A participant must lose at least 3 kg (6.61 pounds) in the first six months in order to continue.

Therapy would consist of screening for obesity, a dietary assessment, intensive behavioral counseling and therapy to promote weight loss through diet and exercise. 

Obesity is defined as a body mass index (BMI) greater than 30 kg/m2. One third of U.S. adults are obese and at higher risk for cardiovascular diseases, diabetes and cancer.

To qualify for the therapy coverage, obese beneficiaries would have to be competent and meet with a qualified primary care provider, according to an Aug. 31 CMS memo. Nursing facilities would not be reimbursed for such therapy care but would benefit by having a lighter, healthier population to serve.
close

Next Article in News

More in News

Government initiatives aim to decrease number of disabled people in nursing homes

Government initiatives aim to decrease number of disabled ...

The federal government is ramping up efforts to reduce the number of disabled people in nursing homes through interagency initiatives. While many disabled people have already been moved out of ...

Nursing home optometrist faces False Claims suit alleging excessive, unreasonable eye exams ...

An optometrist in Kentucky defrauded Medicare and Medicaid by filing claims for nursing home care that was unnecessary or not provided, alleges a False Claims Act lawsuit recently brought by the federal government.

Fecal transplants to treat C. diff now need FDA approval

The Food and Drug Administration is moving to tighten regulations around fecal transplants, which research has shown to be an effective treatment for Clostridium difficile infection.